表紙:ジェネリックがん治療薬の世界市場:がん患者の増加とジェネリックがん治療薬の費用対効果が市場成長を促進
市場調査レポート
商品コード
1221104

ジェネリックがん治療薬の世界市場:がん患者の増加とジェネリックがん治療薬の費用対効果が市場成長を促進

Rising Cases of Cancer and the Cost Effectiveness of Generic Oncology Drugs will Propel Market Growth over the Forecast Period

出版日: | 発行: Persistence Market Research | ページ情報: 英文 176 Pages | 納期: 2~5営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.41円
ジェネリックがん治療薬の世界市場:がん患者の増加とジェネリックがん治療薬の費用対効果が市場成長を促進
出版日: 2022年12月30日
発行: Persistence Market Research
ページ情報: 英文 176 Pages
納期: 2~5営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、世界のジェネリックがん治療薬市場を調査しており、市場の概要、市場規模や予測、動向、促進要因・抑制要因、分子タイプ別・投与経路別・流通チャネル別・地域別の分析、および競合分析などを提供しています。

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場範囲/分類法
  • 市場の定義/範囲/制限
  • 包含と除外

第3章 主要な市場動向

  • 市場に影響を与える主要な動向
  • 製品革新・開発動向

第4章 主な成功要因

  • 製品採用分析
  • 使用状況分析 - 主な統計
  • バリューチェーン分析
  • 最近の製品承認/発売
  • 主な規制 :地域別
  • 製品のUSP分析
  • パイプライン評価

第5章 市場の背景

  • マクロ経済要因
    • 世界のGDP成長の見通し
    • 世界の医療費の概要
    • 世界のジェネリック医薬品市場の見通し
  • 予測要因 - 関連性と影響
    • がんの有病率の上昇
    • ジェネリック医薬品承認の増加
    • がん患者の増加
    • 合併と買収
    • 規制方針
    • 最近の製品承認
    • 製品パイプライン
    • 広告と推薦
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会分析

第6章 COVID-19危機分析

  • COVID-19と影響分析
    • 分子タイプ別
    • 投与経路別
    • 流通チャネル別
    • 地域別
  • 2022年の市場シナリオ

第7章 世界のジェネリックがん治療薬市場の需要の分析と予測

  • 過去の市場分析
  • 現在および将来の市場予測
    • 前年比成長トレンド分析の分析

第8章 世界のジェネリックがん治療薬市場の分析と予測:分子タイプ別

  • イントロダクション/主な調査結果
  • 過去の市場分析:分子タイプ別
  • 現在および将来の市場分析と予測:分子タイプ別
    • 高分子
    • 低分子
  • 市場魅力分析:分子タイプ別

第9章 世界のジェネリックがん治療薬市場の分析と予測:投与経路別

  • イントロダクション/主な調査結果
  • 過去の市場分析:投与経路別
  • 現在および将来の市場分析と予測:投与経路別
    • 経口
    • 非経口
  • 市場魅力度分析:投与経路別

第10章 世界のジェネリックがん治療薬市場の分析と予測:流通チャネル別

  • イントロダクション/主な調査結果
  • 過去の市場分析:流通チャネル別
  • 現在および将来の市場分析と予測: 流通チャネル別
    • 病院薬局
    • 小売薬局
    • オンライン薬局
    • マネージドケア機関
  • 市場魅力分析:流通チャネル別

第11章 世界のジェネリックがん治療薬市場の分析と予測:地域別

  • イントロダクション
  • 過去の市場分析:地域別
  • 現在および将来の市場分析と予測:地域別
    • 北米
    • ラテンアメリカ
    • 欧州
    • 東アジア
    • 南アジア
    • オセアニア
    • 中東・アフリカ
  • 市場魅力度分析:地域別

第12章 北米のジェネリックがん治療薬市場の分析と予測

  • イントロダクション
  • 過去の市場分析: 市場分類別
  • 現在および将来の市場分析と予測:市場分類別
    • 国別
    • 分子タイプ別
    • 投与経路別
    • 流通チャネル別
  • 市場魅力分析
    • 国別
    • 分子タイプ別
    • 投与経路別
    • 流通チャネル別
  • 市場動向
  • 主要な市場参入企業 - 強度マッピング
  • 促進要因と抑制要因 - 影響分析
  • 国レベルの分析と予測
    • 米国のジェネリックがん治療薬市場分析
    • カナダのジェネリックがん治療薬市場分析

第13章 ラテンアメリカのジェネリックがん治療薬市場の分析と予測

  • イントロダクション
  • 過去の市場分析: 市場分類別
  • 現在および将来の市場分析と予測:市場分類別
    • 国別
    • 分子タイプ別
    • 投与経路別
    • 流通チャネル別
  • 市場魅力分析
    • 国別
    • 分子タイプ別
    • 投与経路別
    • 流通チャネル別
  • 市場動向
  • 主要な市場参入企業 - 強度マッピング
  • 促進要因と抑制要因 - 影響分析
  • 国レベルの分析と予測
    • メキシコのジェネリックがん治療薬市場分析
    • ブラジルのジェネリックがん治療薬市場分析
    • アルゼンチンのジェネリックがん治療薬市場分析

第14章 欧州のジェネリックがん治療薬市場の分析と予測

  • イントロダクション
  • 過去の市場分析: 市場分類別
  • 現在および将来の市場分析と予測:市場分類別
    • 国別
    • 分子タイプ別
    • 投与経路別
    • 流通チャネル別
  • 市場魅力分析
    • 国別
    • 分子タイプ別
    • 投与経路別
    • 流通チャネル別
  • 市場動向
  • 主要な市場参入企業 - 強度マッピング
  • 促進要因と抑制要因 - 影響分析
  • 国レベルの分析と予測
    • ドイツのジェネリックがん治療薬市場分析
    • イタリアのジェネリックがん治療薬市場分析
    • フランスのジェネリックがん治療薬市場分析
    • 英国のジェネリックがん治療薬市場分析
    • スペインのジェネリックがん治療薬市場分析
    • ベネルクスのジェネリックがん治療薬市場分析
    • ロシアのジェネリックがん治療薬市場分析

第15章 東アジアのジェネリックがん治療薬市場の分析と予測

  • イントロダクション
  • 過去の市場分析: 市場分類別
  • 現在および将来の市場分析と予測:市場分類別
    • 国別
    • 分子タイプ別
    • 投与経路別
    • 流通チャネル別
  • 市場魅力分析
    • 分子タイプ別
    • 投与経路別
    • 流通チャネル別
  • 市場動向
  • 主要な市場参入企業 - 強度マッピング
  • 促進要因と抑制要因 - 影響分析
  • 国レベルの分析と予測
    • 中国のジェネリックがん治療薬市場分析
    • 日本のジェネリックがん治療薬市場分析
    • 韓国のジェネリックがん治療薬市場分析

第16章 南アジアのジェネリックがん治療薬市場の分析と予測

  • イントロダクション
  • 過去の市場分析: 市場分類別
  • 現在および将来の市場分析と予測:市場分類別
    • 国別
    • 分子タイプ別
    • 投与経路別
    • 流通チャネル別
  • 市場魅力分析
    • 国別
    • 分子タイプ別
    • 投与経路別
    • 流通チャネル別
  • 市場動向
  • 主要な市場参入企業 - 強度マッピング
  • 促進要因と抑制要因 - 影響分析
  • 国レベルの分析と予測
    • インドのジェネリックがん治療薬市場分析
    • インドネシアのジェネリックがん治療薬市場分析
    • マレーシアのジェネリックがん治療薬市場分析
    • タイのジェネリックがん治療薬市場分析

第17章 オセアニアのジェネリックがん治療薬市場と予測

  • イントロダクション
  • 過去の市場分析: 市場分類別
  • 現在および将来の市場分析と予測:市場分類別
    • 国別
    • 分子タイプ別
    • 投与経路別
    • 流通チャネル別
  • 市場魅力分析
    • 国別
    • 分子タイプ別
    • 投与経路別
    • 流通チャネル別
  • 主要な市場参入企業 - 強度マッピング
  • 主要な市場参入企業 - 強度マッピング
  • 促進要因と抑制要因 - 影響分析
  • 国レベルの分析と予測
    • オーストラリアのジェネリックがん治療薬市場分析
    • ニュージーランドのジェネリックがん治療薬市場分析

第18章 中東・アフリカのジェネリックがん治療薬市場分析と予測

  • イントロダクション
  • 過去の市場分析: 市場分類別
  • 現在および将来の市場分析と予測:市場分類別
    • 国別
    • 分子タイプ別
    • 投与経路別
    • 流通チャネル別
  • 市場魅力分析
    • 国別
    • 分子タイプ別
    • 投与経路別
    • 流通チャネル別
  • 市場動向
  • 主要な市場参入企業 - 強度マッピング
  • 促進要因と抑制要因 - 影響分析
  • 国レベルの分析と予測
    • GCC諸国のジェネリックがん治療薬市場分析
    • トルコのジェネリックがん治療薬市場分析
    • 南アフリカのジェネリックがん治療薬市場分析
    • 北アフリカのジェネリックがん治療薬市場分析

第19章 市場構造分析

  • 市場分析:企業層別
  • 主要企業の市場シェア分析
  • 市場集中
  • 市場プレゼンス分析

第20章 競合分析

  • 競合ダッシュボード
  • 競合の詳細
    • Bausch Health Companies Inc.
    • Novartis
    • Pfizer
    • GSK
    • Celgene
    • Teva Pharmaceuticals
    • Merck & Company
    • Aurobindo Pharma
    • Hikma Pharmaceuticals
    • Mylan
    • NATCO Pharma

第21章 使用される前提条件と頭字語

第22章 調査手法

図表

List of Tables

  • Table 01: Global Generic Oncology Drugs Market Value (US$ Mn) Analysis 2013-2022 and Forecast 2023-2033, By Molecule Type
  • Table 02: Global Generic Oncology Drugs Market Value (US$ Mn) Analysis 2013-2022 and Forecast 2023-2033by Route of Administration
  • Table 03: Global Generic Oncology Drugs Market Value (US$ Mn) Analysis 2013-2022 and Forecast 2023-2033, By Distribution Channel
  • Table 04: Global Generic Oncology Drugs Market Value (US$ Mn) Analysis 2013-2022 and Forecast 2023-2033, By Region
  • Table 05: North America Generic Oncology Drugs Market Value (US$ Mn) Analysis 2013-2022 and Forecast 2023-2033, By Country
  • Table 06: North America Generic Oncology Drugs Market Value (US$ Mn) Analysis 2013-2022 and Forecast 2023-2033, By Molecule Type
  • Table 07: North America Generic Oncology Drugs Market Value (US$ Mn) Analysis 2013-2022 and Forecast 2023-2033, By Route of Administration
  • Table 08: North America Generic Oncology Drugs Market Value (US$ Mn) Analysis 2013-2022 and Forecast 2023-2033, By Distribution Channel
  • Table 09: Latin America Generic Oncology Drugs Market Value (US$ Mn) Analysis 2013-2022 and Forecast 2023-2033, By Country
  • Table 10: Latin America Generic Oncology Drugs Market Value (US$ Mn) Analysis 2013-2022 and Forecast 2023-2033, By Molecule Type
  • Table 11: Latin America Generic Oncology Drugs Market Value (US$ Mn) Analysis 2013-2022 and Forecast 2023-2033, By Route of Administration
  • Table 12: Latin America Generic Oncology Drugs Market Value (US$ Mn) Analysis 2013-2022 and Forecast 2023-2033, By Distribution Channel
  • Table 13: Europe Generic Oncology Drugs Market Value (US$ Mn) Analysis 2013-2022 and Forecast 2023-2033, By Country
  • Table 14: Europe Generic Oncology Drugs Market Value (US$ Mn) Analysis 2013-2022 and Forecast 2023-2033, By Molecule Type
  • Table 15: Europe Generic Oncology Drugs Market Value (US$ Mn) Analysis 2013-2022 and Forecast 2023-2033by Route of Administration
  • Table 16: Europe Generic Oncology Drugs Market Value (US$ Mn) Analysis 2013-2022 and Forecast 2023-2033, By Distribution Channel
  • Table 17: East Asia Generic Oncology Drugs Market Value (US$ Mn) Analysis 2013-2022 and Forecast 2023-2033, By Country
  • Table 18: East Asia Generic Oncology Drugs Market Value (US$ Mn) Analysis 2013-2022 and Forecast 2023-2033, By Molecule Type
  • Table 19: East Asia Generic Oncology Drugs Market Value (US$ Mn) Analysis 2013-2022 and Forecast 2023-2033, By Route of Administration
  • Table 20: East Asia Generic Oncology Drugs Market Value (US$ Mn) Analysis 2013-2022 and Forecast 2023-2033, By Distribution Channel
  • Table 21: South Asia Generic Oncology Drugs Market Value (US$ Mn) Analysis 2013-2022 and Forecast 2023-2033, By Country
  • Table 22: South Asia Generic Oncology Drugs Market Value (US$ Mn) Analysis 2013-2022 and Forecast 2023-2033, By Molecule Type
  • Table 23: South Asia Generic Oncology Drugs Market Value (US$ Mn) Analysis 2013-2022 and Forecast 2023-2033, By Route of Administration
  • Table 24: South Asia Generic Oncology Drugs Market Value (US$ Mn) Analysis 2013-2022 and Forecast 2023-2033, By Distribution Channel
  • Table 25: Oceania Generic Oncology Drugs Market Value (US$ Mn) Analysis 2013-2022 and Forecast 2023-2033, By Country
  • Table 26: Oceania Generic Oncology Drugs Market Value (US$ Mn) Analysis 2013-2022 and Forecast 2023-2033, By Molecule Type
  • Table 27: Oceania Generic Oncology Drugs Market Analysis 2013-2022 and Forecast 2023-2033by Route of Administration
  • Table 28: Oceania Generic Oncology Drugs Market Value (US$ Mn) Analysis 2013-2022 and Forecast 2023-2033, By Distribution Channel
  • Table 29: Middle East & Africa Generic Oncology Drugs Market Value (US$ Mn) Analysis 2013-2022 and Forecast 2023-2033, By Country
  • Table 30: Middle East & Africa Generic Oncology Drugs Market Value (US$ Mn) Analysis 2013-2022 and Forecast 2023-2033, By Molecule Type
  • Table 31: Middle East & Africa Generic Oncology Drugs Market Analysis 2013-2022 and Forecast 2023-2033by Route of Administration
  • Table 32: Middle East & Africa Generic Oncology Drugs Market Value (US$ Mn) Analysis 2013-2022 and Forecast 2023-2033, By Distribution Channel

List of Figures

  • Figure 01: Global Generic Oncology Drugs Market Value (US$ Mn) Analysis, 2013-2022
  • Figure 02: Global Generic Oncology Drugs Market Forecast & Y-O-Y Growth, 2023-2033
  • Figure 03: Global Generic Oncology Drugs Market Absolute $ Opportunity (US$ Mn) Analysis, 2022-2033
  • Figure 04: Global Generic Oncology Drugs Market Value Share (%) Analysis 2023 and 2033, By Molecule Type
  • Figure 05: Global Generic Oncology Drugs Market Y-O-Y Growth (%) Analysis 2022-2033, By Molecule Type
  • Figure 06: Global Generic Oncology Drugs Market Attractiveness Analysis 2023-2033, By Molecule Type
  • Figure 07: Global Generic Oncology Drugs Market Value Share (%) Analysis 2023 and 2033, By Route of Administration
  • Figure 08: Global Generic Oncology Drugs Market Y-O-Y Growth (%) Analysis 2022-2033, By Route of Administration
  • Figure 09: Global Generic Oncology Drugs Market Attractiveness Analysis 2023-2033, By Route of Administration
  • Figure 10: Global Generic Oncology Drugs Market Value Share (%) Analysis 2023 and 2033, By Distribution Channel
  • Figure 11: Global Generic Oncology Drugs Market Y-O-Y Growth (%) Analysis 2022-2033, By Distribution Channel
  • Figure 12: Global Generic Oncology Drugs Market Attractiveness Analysis 2023-2033, By Distribution Channel
  • Figure 13: Global Generic Oncology Drugs Market Value Share (%) Analysis 2023 and 2033, By Region
  • Figure 14: Global Generic Oncology Drugs Market Y-O-Y Growth (%) Analysis 2022-2033, By Region
  • Figure 15: Global Generic Oncology Drugs Market Attractiveness Analysis 2023-2033, By Region
  • Figure 16: North America Generic Oncology Drugs Market Value (US$ Mn) Analysis, 2013-2022
  • Figure 17: North America Generic Oncology Drugs Market Value (US$ Mn) Forecast, 2023-2033
  • Figure 18: North America Generic Oncology Drugs Market Value Share, By Molecule Type (2023 E)
  • Figure 19: North America Generic Oncology Drugs Market Value Share, By Route of Administration (2023 E)
  • Figure 20: North America Generic Oncology Drugs Market Value Share, By Distribution Channel (2023 E)
  • Figure 21: North America Generic Oncology Drugs Market Value Share, By Country (2023 E)
  • Figure 22: North America Generic Oncology Drugs Market Attractiveness Analysis By Molecule Type, 2023-2033
  • Figure 23: North America Generic Oncology Drugs Market Attractiveness Analysis By Route of Administration, 2023-2033
  • Figure 24: North America Generic Oncology Drugs Market Attractiveness Analysis By Distribution Channel, 2023-2033
  • Figure 25: North America Generic Oncology Drugs Market Attractiveness Analysis By Country, 2023-2033
  • Figure 26: U.S. Generic Oncology Drugs Market Value Proportion Analysis, 2022
  • Figure 27: Global Vs. U.S. Growth Comparison, 2022 - 2033
  • Figure 28: U.S. Generic Oncology Drugs Market Share Analysis (%) By Molecule Type, 2022 & 2033
  • Figure 29: U.S. Generic Oncology Drugs Market Share Analysis (%) By Route of Administration, 2022 & 2033
  • Figure 30: U.S. Generic Oncology Drugs Market Share Analysis (%) By Distribution Channel, 2022 & 2033
  • Figure 31: Canada Generic Oncology Drugs Market Value Proportion Analysis, 2022
  • Figure 32: Global Vs. Canada. Growth Comparison, 2022 - 2033
  • Figure 33: Canada Generic Oncology Drugs Market Share Analysis (%) By Molecule Type, 2022 & 2033
  • Figure 34: Canada Generic Oncology Drugs Market Share Analysis (%) By Route of Administration, 2022 & 2033
  • Figure 35: Canada Generic Oncology Drugs Market Share Analysis (%) By Distribution Channel, 2022 & 2033
  • Figure 36: Latin America Generic Oncology Drugs Market Value (US$ Mn) Analysis, 2013-2022
  • Figure 37: Latin America Generic Oncology Drugs Market Value (US$ Mn) Forecast, 2023-2033
  • Figure 38: Latin America Generic Oncology Drugs Market Value Share, By Molecule Type (2023 E)
  • Figure 39: Latin America Generic Oncology Drugs Market Value Share, By Route of Administration (2023 E)
  • Figure 40: Latin America Generic Oncology Drugs Market Value Share, By Distribution Channel (2023 E)
  • Figure 41: Latin America Generic Oncology Drugs Market Value Share, By Country (2023 E)
  • Figure 42: Latin America Generic Oncology Drugs Market Attractiveness Analysis By Molecule Type, 2023-2033
  • Figure 43: Latin America Generic Oncology Drugs Market Attractiveness Analysis By Route of Administration, 2023-2033
  • Figure 44: Latin America Generic Oncology Drugs Market Attractiveness Analysis By Distribution Channel, 2023-2033
  • Figure 45: Latin America Generic Oncology Drugs Market Attractiveness Analysis By Country, 2023-2033
  • Figure 46: Mexico Generic Oncology Drugs Market Value Proportion Analysis, 2022
  • Figure 47: Global Vs Mexico Growth Comparison, 2022 - 2033
  • Figure 48: Mexico Generic Oncology Drugs Market Share Analysis (%) By Molecule Type, 2022 & 2033
  • Figure 49: Mexico Generic Oncology Drugs Market Share Analysis (%) By Route of Administration, 2022 & 2033
  • Figure 50: Mexico Generic Oncology Drugs Market Share Analysis (%) By Distribution Channel, 2022 & 2033
  • Figure 51: Brazil Generic Oncology Drugs Market Value Proportion Analysis, 2022
  • Figure 52: Global Vs. Brazil. Growth Comparison, 2022 - 2033
  • Figure 53: Brazil Generic Oncology Drugs Market Share Analysis (%) By Molecule Type, 2022 & 2033
  • Figure 54: Brazil Generic Oncology Drugs Market Share Analysis (%) By Route of Administration, 2022 & 2033
  • Figure 55: Brazil Generic Oncology Drugs Market Share Analysis (%) By Distribution Channel, 2022 & 2033
  • Figure 56: Argentina Generic Oncology Drugs Market Value Proportion Analysis, 2022
  • Figure 57: Global Vs Argentina Growth Comparison, 2022 - 2033
  • Figure 58: Argentina Generic Oncology Drugs Market Share Analysis (%) By Molecule Type, 2022 & 2033
  • Figure 59: Argentina Generic Oncology Drugs Market Share Analysis (%) By Route of Administration, 2022 & 2033
  • Figure 60: Argentina Generic Oncology Drugs Market Share Analysis (%) By Distribution Channel, 2022 & 2033
  • Figure 61: Europe Generic Oncology Drugs Market Value (US$ Mn) Analysis, 2013-2022
  • Figure 62: Europe Generic Oncology Drugs Market Value (US$ Mn) Forecast, 2023-2033
  • Figure 63: Europe Generic Oncology Drugs Market Value Share, By Molecule Type (2023 E)
  • Figure 64: Europe Generic Oncology Drugs Market Value Share, By Route of Administration (2023 E)
  • Figure 65: Europe Generic Oncology Drugs Market Value Share, By Distribution Channel (2023 E)
  • Figure 66: Europe Generic Oncology Drugs Market Value Share, By Country (2023 E)
  • Figure 67: Europe Generic Oncology Drugs Market Attractiveness Analysis By Molecule Type, 2023-2033
  • Figure 68: Europe Generic Oncology Drugs Market Attractiveness Analysis By Route of Administration, 2023-2033
  • Figure 69: Europe Generic Oncology Drugs Market Attractiveness Analysis By Distribution Channel, 2023-2033
  • Figure 70: Europe Generic Oncology Drugs Market Attractiveness Analysis By Country, 2023-2033
  • Figure 71: UK Generic Oncology Drugs Market Value Proportion Analysis, 2022
  • Figure 72: Global Vs. UK Growth Comparison, 2022 - 2033
  • Figure 73: UK Generic Oncology Drugs Market Share Analysis (%) By Molecule Type, 2022 & 2033
  • Figure 74: UK Generic Oncology Drugs Market Share Analysis (%) By Route of Administration, 2022 & 2033
  • Figure 75: UK Generic Oncology Drugs Market Share Analysis (%) By Distribution Channel, 2022 & 2033
  • Figure 76: Germany Generic Oncology Drugs Market Value Proportion Analysis, 2022
  • Figure 77: Global Vs. Germany Growth Comparison, 2022 - 2033
  • Figure 78: Germany Generic Oncology Drugs Market Share Analysis (%) By Molecule Type, 2022 & 2033
  • Figure 79: Germany Generic Oncology Drugs Market Share Analysis (%) By Route of Administration, 2022 & 2033
  • Figure 80: Germany Generic Oncology Drugs Market Share Analysis (%) By Distribution Channel, 2022 & 2033
  • Figure 81: Italy Generic Oncology Drugs Market Value Proportion Analysis, 2022
  • Figure 82: Global Vs. Italy Growth Comparison, 2022 - 2033
  • Figure 83: Italy Generic Oncology Drugs Market Share Analysis (%) By Molecule Type, 2022 & 2033
  • Figure 84: Italy Generic Oncology Drugs Market Share Analysis (%) By Route of Administration, 2022 & 2033
  • Figure 85: Italy Generic Oncology Drugs Market Share Analysis (%) By Distribution Channel, 2022 & 2033
  • Figure 86: France Generic Oncology Drugs Market Value Proportion Analysis, 2022
  • Figure 87: Global Vs France Growth Comparison, 2022 - 2033
  • Figure 88: France Generic Oncology Drugs Market Share Analysis (%) By Molecule Type, 2022 & 2033
  • Figure 89: France Generic Oncology Drugs Market Share Analysis (%) By Route of Administration, 2022 & 2033
  • Figure 90: France Generic Oncology Drugs Market Share Analysis (%) By Distribution Channel, 2022 & 2033
  • Figure 91: Spain Generic Oncology Drugs Market Value Proportion Analysis, 2022
  • Figure 92: Global Vs Spain Growth Comparison, 2022 - 2033
  • Figure 93: Spain Generic Oncology Drugs Market Share Analysis (%) By Molecule Type, 2022 & 2033
  • Figure 94: Spain Generic Oncology Drugs Market Share Analysis (%) By Route of Administration, 2022 & 2033
  • Figure 95: Spain Generic Oncology Drugs Market Share Analysis (%) By Distribution Channel, 2022 & 2033
  • Figure 96: Russia Generic Oncology Drugs Market Value Proportion Analysis, 2022
  • Figure 97: Global Vs Russia Growth Comparison, 2022 - 2033
  • Figure 98: Russia Generic Oncology Drugs Market Share Analysis (%) By Molecule Type, 2022 & 2033
  • Figure 99: Russia Generic Oncology Drugs Market Share Analysis (%) By Route of Administration, 2022 & 2033
  • Figure 100: Russia Generic Oncology Drugs Market Share Analysis (%) By Distribution Channel, 2022 & 2033
  • Figure 101: Benelux Generic Oncology Drugs Market Value Proportion Analysis, 2022
  • Figure 102: Global Vs Benelux Growth Comparison, 2022 - 2033
  • Figure 103: Benelux Generic Oncology Drugs Market Share Analysis (%) By Molecule Type, 2022 & 2033
  • Figure 104: Benelux Generic Oncology Drugs Market Share Analysis (%) By Route of Administration, 2022 & 2033
  • Figure 105: Benelux Generic Oncology Drugs Market Share Analysis (%) By Distribution Channel, 2022 & 2033
  • Figure 106: East Asia Generic Oncology Drugs Market Value (US$ Mn) Analysis, 2013-2022
  • Figure 107: East Asia Generic Oncology Drugs Market Value (US$ Mn) Forecast, 2023-2033
  • Figure 108: East Asia Generic Oncology Drugs Market Value Share, By Molecule Type (2023 E)
  • Figure 109: East Asia Generic Oncology Drugs Market Value Share, By Route of Administration (2023 E)
  • Figure 110: East Asia Generic Oncology Drugs Market Value Share, By Distribution Channel (2023 E)
  • Figure 111: East Asia Generic Oncology Drugs Market Value Share, By Country (2023 E)
  • Figure 112: East Asia Generic Oncology Drugs Market Attractiveness Analysis By Molecule Type, 2023-2033
  • Figure 113: East Asia Generic Oncology Drugs Market Attractiveness Analysis By Route of Administration, 2023-2033
  • Figure 114: East Asia Generic Oncology Drugs Market Attractiveness Analysis By Distribution Channel, 2023-2033
  • Figure 115: East Asia Generic Oncology Drugs Market Attractiveness Analysis By Country, 2023-2033
  • Figure 116: China Generic Oncology Drugs Market Value Proportion Analysis, 2022
  • Figure 117: Global Vs. China Growth Comparison, 2022 - 2033
  • Figure 118: China Generic Oncology Drugs Market Share Analysis (%) By Molecule Type, 2022 & 2033
  • Figure 119: China Generic Oncology Drugs Market Share Analysis (%) By Route of Administration, 2022 & 2033
  • Figure 120: China Generic Oncology Drugs Market Share Analysis (%) By Distribution Channel, 2022 & 2033
  • Figure 121: Japan Generic Oncology Drugs Market Value Proportion Analysis, 2022
  • Figure 122: Global Vs. Japan Growth Comparison, 2022 - 2033
  • Figure 123: Japan Generic Oncology Drugs Market Share Analysis (%) By Molecule Type, 2022 & 2033
  • Figure 124: Japan Generic Oncology Drugs Market Share Analysis (%) By Route of Administration, 2022 & 2033
  • Figure 125: Japan Generic Oncology Drugs Market Share Analysis (%) By Distribution Channel, 2022 & 2033
  • Figure 126: South Korea Generic Oncology Drugs Market Value Proportion Analysis, 2022
  • Figure 127: Global Vs South Korea Growth Comparison, 2022 - 2033
  • Figure 128: South Korea Generic Oncology Drugs Market Share Analysis (%) By Molecule Type, 2022 & 2033
  • Figure 129: South Korea Generic Oncology Drugs Market Share Analysis (%) By Route of Administration, 2022 & 2033
  • Figure 130: South Korea Generic Oncology Drugs Market Share Analysis (%) By Distribution Channel, 2022 & 2033
  • Figure 131: South Asia Generic Oncology Drugs Market Value (US$ Mn) Analysis, 2013-2022
  • Figure 132: South Asia Generic Oncology Drugs Market Value (US$ Mn) Forecast, 2023-2033
  • Figure 133: South Asia Generic Oncology Drugs Market Value Share, By Molecule Type (2023 E)
  • Figure 134: South Asia Generic Oncology Drugs Market Value Share, By Route of Administration (2023 E)
  • Figure 135: South Asia Generic Oncology Drugs Market Value Share, By Distribution Channel (2023 E)
  • Figure 136: South Asia Generic Oncology Drugs Market Value Share, By Country (2023 E)
  • Figure 137: South Asia Generic Oncology Drugs Market Attractiveness Analysis By Molecule Type, 2023-2033
  • Figure 138: South Asia Generic Oncology Drugs Market Attractiveness Analysis By Route of Administration, 2023-2033
  • Figure 139: South Asia Generic Oncology Drugs Market Attractiveness Analysis By Distribution Channel, 2023-2033
  • Figure 140: South Asia Generic Oncology Drugs Market Attractiveness Analysis By Country, 2023-2033
  • Figure 141: India Generic Oncology Drugs Market Value Proportion Analysis, 2022
  • Figure 142: Global Vs. India Growth Comparison, 2022 - 2033
  • Figure 143: India Generic Oncology Drugs Market Share Analysis (%) By Molecule Type, 2022 & 2033
  • Figure 144: India Generic Oncology Drugs Market Share Analysis (%) By Route of Administration, 2022 & 2033
  • Figure 145: India Generic Oncology Drugs Market Share Analysis (%) By Distribution Channel, 2022 & 2033
  • Figure 146: Indonesia Generic Oncology Drugs Market Value Proportion Analysis, 2022
  • Figure 147: Global Vs. Indonesia Growth Comparison, 2022 - 2033
  • Figure 148: Indonesia Generic Oncology Drugs Market Share Analysis (%) By Molecule Type, 2022 & 2033
  • Figure 149: Indonesia Generic Oncology Drugs Market Share Analysis (%) By Route of Administration, 2022 & 2033
  • Figure 150: Indonesia Generic Oncology Drugs Market Share Analysis (%) By Distribution Channel, 2022 & 2033
  • Figure 151: Malaysia Generic Oncology Drugs Market Value Proportion Analysis, 2022
  • Figure 152: Global Vs. Malaysia Growth Comparison, 2022 - 2033
  • Figure 153: Malaysia Generic Oncology Drugs Market Share Analysis (%) By Molecule Type, 2022 & 2033
  • Figure 154: Malaysia Generic Oncology Drugs Market Share Analysis (%) By Route of Administration, 2022 & 2033
  • Figure 155: Malaysia Generic Oncology Drugs Market Share Analysis (%) By Distribution Channel, 2022 & 2033
  • Figure 156: Thailand Generic Oncology Drugs Market Value Proportion Analysis, 2022
  • Figure 157: Global Vs. Thailand Growth Comparison, 2022 - 2033
  • Figure 158: Thailand Generic Oncology Drugs Market Share Analysis (%) By Molecule Type, 2022 & 2033
  • Figure 159: Thailand Generic Oncology Drugs Market Share Analysis (%) By Route of Administration, 2022 & 2033
  • Figure 160: Thailand Generic Oncology Drugs Market Share Analysis (%) By Distribution Channel, 2022 & 2033
  • Figure 161: Oceania Generic Oncology Drugs Market Value (US$ Mn) Analysis, 2013-2022
  • Figure 162: Oceania Generic Oncology Drugs Market Value (US$ Mn) Forecast, 2023-2033
  • Figure 163: Oceania Generic Oncology Drugs Market Value Share, By Molecule Type (2023 E)
  • Figure 164: Oceania Generic Oncology Drugs Market Value Share, By Route of Administration (2023 E)
  • Figure 165: Oceania Generic Oncology Drugs Market Value Share, By Distribution Channel (2023 E)
  • Figure 166: Oceania Generic Oncology Drugs Market Value Share, By Country (2023 E)
  • Figure 167: Oceania Generic Oncology Drugs Market Attractiveness Analysis By Molecule Type, 2023-2033
  • Figure 168: Oceania Generic Oncology Drugs Market Attractiveness Analysis By Route of Administration, 2023-2033
  • Figure 169: Oceania Generic Oncology Drugs Market Attractiveness Analysis By Distribution Channel, 2023-2033
  • Figure 170: Oceania Generic Oncology Drugs Market Attractiveness Analysis By Country, 2023-2033
  • Figure 171: Australia Generic Oncology Drugs Market Value Proportion Analysis, 2022
  • Figure 172: Global Vs. Australia Growth Comparison, 2022 - 2033
  • Figure 173: Australia Generic Oncology Drugs Market Share Analysis (%) By Molecule Type, 2022 & 2033
  • Figure 174: Australia Generic Oncology Drugs Market Share Analysis (%) By Route of Administration, 2022 & 2033
  • Figure 175: Australia Generic Oncology Drugs Market Share Analysis (%) By Distribution Channel, 2022 & 2033
  • Figure 176: New Zealand Generic Oncology Drugs Market Value Proportion Analysis, 2022
  • Figure 177: Global Vs New Zealand Growth Comparison, 2022 - 2033
  • Figure 178: New Zealand Generic Oncology Drugs Market Share Analysis (%) By Molecule Type, 2022 & 2033
  • Figure 179: New Zealand Generic Oncology Drugs Market Share Analysis (%) By Route of Administration, 2022 & 2033
  • Figure 180: New Zealand Generic Oncology Drugs Market Share Analysis (%) By Distribution Channel, 2022 & 2033
  • Figure 181: Middle East & Africa Generic Oncology Drugs Market Value (US$ Mn) Analysis, 2013-2022
  • Figure 182: Middle East & Africa Generic Oncology Drugs Market Value (US$ Mn) Forecast, 2023-2033
  • Figure 183: Middle East & Africa Generic Oncology Drugs Market Value Share, By Molecule Type (2023 E)
  • Figure 184: Middle East & Africa Generic Oncology Drugs Market Value Share, By Route of Administration (2023 E)
  • Figure 185: Middle East & Africa Generic Oncology Drugs Market Value Share, By Distribution Channel (2023 E)
  • Figure 186: Middle East & Africa Generic Oncology Drugs Market Value Share, By Country (2023 E)
  • Figure 187: Middle East & Africa Generic Oncology Drugs Market Attractiveness Analysis By Molecule Type, 2023-2033
  • Figure 188: Middle East & Africa Generic Oncology Drugs Market Attractiveness Analysis By Route of Administration, 2023-2033
  • Figure 189: Middle East & Africa Generic Oncology Drugs Market Attractiveness Analysis By Distribution Channel, 2023-2033
  • Figure 190: Middle East & Africa Generic Oncology Drugs Market Attractiveness Analysis By Country, 2023-2033
  • Figure 191: GCC Countries Generic Oncology Drugs Market Value Proportion Analysis, 2022
  • Figure 192: Global Vs GCC Countries Growth Comparison, 2022 - 2033
  • Figure 193: GCC Countries Generic Oncology Drugs Market Share Analysis (%) By Molecule Type, 2022 & 2033
  • Figure 194: GCC Countries Generic Oncology Drugs Market Share Analysis (%) By Route of Administration, 2022 & 2033
  • Figure 195: GCC Countries Generic Oncology Drugs Market Share Analysis (%) By Distribution Channel, 2022 & 2033
  • Figure 196: Turkey Generic Oncology Drugs Market Value Proportion Analysis, 2022
  • Figure 197: Global Vs. Turkey Growth Comparison, 2022 - 2033
  • Figure 198: Turkey Generic Oncology Drugs Market Share Analysis (%) By Molecule Type, 2022 & 2033
  • Figure 199: Turkey Generic Oncology Drugs Market Share Analysis (%) By Route of Administration, 2022 & 2033
  • Figure 200: Turkey Generic Oncology Drugs Market Share Analysis (%) By Distribution Channel, 2022 & 2033
  • Figure 201: South Africa Generic Oncology Drugs Market Value Proportion Analysis, 2022
  • Figure 202: Global Vs. South Africa Growth Comparison, 2022 - 2033
  • Figure 203: South Africa Generic Oncology Drugs Market Share Analysis (%) By Molecule Type, 2022 & 2033
  • Figure 204: South Africa Generic Oncology Drugs Market Share Analysis (%) By Route of Administration, 2022 & 2033
  • Figure 205: South Africa Generic Oncology Drugs Market Share Analysis (%) By Distribution Channel, 2022 & 2033
  • Figure 206: North Africa Generic Oncology Drugs Market Value Proportion Analysis, 2022
  • Figure 207: Global Vs North Africa Growth Comparison, 2022 - 2033
  • Figure 208: North Africa Generic Oncology Drugs Market Share Analysis (%) By Molecule Type, 2022 & 2033
  • Figure 209: North Africa Generic Oncology Drugs Market Share Analysis (%) By Route of Administration, 2022 & 2033
  • Figure 210: North Africa Generic Oncology Drugs Market Share Analysis (%) By Distribution Channel, 2022 & 2033
目次
Product Code: PMRREP25480

Generic Oncology Drugs Market: Scope of Report

The latest publication by Persistence Market Research on the global generic oncology drugs market evaluates the opportunities and current market landscape and provides detailed analysis and updates about corresponding sections affecting the market. The study offers detailed insights into current market dynamics, which include the drivers, restraints, trends, and opportunities in the market. The principal aim of the market study is to present exclusive information about how the market will perform during the forecast period of 2023-2033.

Important indicators for the successful growth of the market are presented in this comprehensive report, which includes a Year-on-Year (Y-o-Y) growth analysis of the market, and compounded annual growth rate (CAGR), which are described exhaustively in Persistence Market Research's study. This research study can support readers to know the demand for generic oncology drugs and the quantitative development opportunities during the study period.

The research is beneficial for shareholders in the landscape, including investors, manufacturers, service providers, distributors, and suppliers, and can help them in developing suitable business strategies to flourish in the generic oncology drugs market. Shareholders in the generic oncology drugs market, industry experts, investors, researchers, and reporters, as well as business enthusiasts can leverage insights and information presented in this Persistence Market Research study.

Market statistics, as well as information linked to the macro- as well as micro-economic variables affecting the business scenario in the generic oncology drugs market, are also included in the current study. Depending on potential developments in the market, substantive insights are also encountered in this report. Additionally, by the data submitted in this report, minor companies and new entrants in the industry can be aided in making suitable company choices to achieve traction in the market.

Key Market Segments

Persistence Market Research's study on the generic oncology drugs market offers information divided into four important segments - molecule type, route of administration, distribution channel and region. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories.

Molecule Type

Large Molecule

Small Molecule

Route of Administration

Oral

Parenteral

Distribution Channel

Hospital Pharmacy

Retail Pharmacy

Online Pharmacies

Managed Care Institutions

Region

North America

Latin America

Europe

South Asia

East Asia

Oceania

MEA

Key Questions Answered in Report:

Which regions will continue to remain the most profitable markets for generic oncology drugs over the coming years?

How will changing trends influence the market?

How has the COVID-19 crisis influenced market growth?

How can market players capture the low-hanging opportunities in developed regions?

What are the strategies of stakeholders in the market to shape their position in this landscape?

What are the restraining factors that investors need to be aware of and might tackle while investing in the market?

What are the developmental trends that will influence the market?

How can companies in the generic oncology drugs market avail themselves of the growth opportunities in developed and emerging sectors?

Research Methodology

In Persistence Market Research's study, a unique research methodology is utilized to conduct extensive research on the growth of the generic oncology drugs market, and reach conclusions on the future growth parameters of the market. This research methodology is a combination of primary and secondary research, which helps analysts to ensure the accuracy and reliability of the conclusions.

Secondary resources referred to by analysts during the production of the market study include statistics from governmental organizations, trade journals, white papers, and internal and external proprietary databases. Analysts have interviewed senior managers, product portfolio managers, CEOs, VPs, marketing/product managers, and market intelligence managers, who contributed to the development of this report as a primary resource.

Comprehensive information acquired from primary and secondary resources acts as validation from companies in the market and makes Persistence Market Research's projections on the growth prospects of the generic oncology drugs market are more accurate and reliable.

Table of Contents

1. Executive Summary

  • 1.1. Global Market Outlook
  • 1.2. Demand Side Trends
  • 1.3. Supply Side Trends
  • 1.4. Analysis and Recommendations

2. Market Overview

  • 2.1. Market Coverage / Taxonomy
  • 2.2. Market Definition / Scope / Limitations
  • 2.3. Inclusions and Exclusions

3. Key Market Trends

  • 3.1. Key Trends Impacting the Market
  • 3.2. Product Innovation / Development Trends

4. Key Success Factors

  • 4.1. Product Adoption Analysis
  • 4.2. Usage Analysis - Key Statistics
  • 4.3. Value Chain Analysis
  • 4.4. Recent Product Approvals/Launches
  • 4.5. Key Regulations - By Region
  • 4.6. Product USP Analysis
  • 4.7. Pipeline Assessment

5. Market Background

  • 5.1. Macroeconomic Factors
    • 5.1.1. Global GDP Growth Outlook
    • 5.1.2. Global Healthcare Expenditure Overview
    • 5.1.3. Global Generic Drugs Market Outlook
  • 5.2. Forecast Factors - Relevance & Impact
    • 5.2.1. Rising Prevalence of Cancer
    • 5.2.2. Increasing Generic Product Approvals
    • 5.2.3. Increasing Cases of Cancer Patients
    • 5.2.4. Mergers and Acquisitions
    • 5.2.5. Regulatory Policies
    • 5.2.6. Recent Product Approvals
    • 5.2.7. Product Pipeline
    • 5.2.8. Advertisements and Endorsements
  • 5.3. Market Dynamics
    • 5.3.1. Drivers
    • 5.3.2. Restraints
    • 5.3.3. Opportunity Analysis

6. COVID-19 Crisis Analysis

  • 6.1. COVID-19 and Impact Analysis
    • 6.1.1. By Molecule Type
    • 6.1.2. By Route of Administration
    • 6.1.3. By Distribution Channel
    • 6.1.4. By Region
  • 6.2. 2022 Market Scenario

7. Global Generic Oncology Drugs Market Demand (in Value US$ Mn) Analysis 2013-2022 and Forecast, 2023-2033

  • 7.1. Historical Market Value (US$ Mn) Analysis, 2013-2022
  • 7.2. Current and Future Market Value (US$ Mn) Projections, 2023-2033
    • 7.2.1. Y-o-Y Growth Trend Analysis
    • 7.2.2. Absolute $ Opportunity Analysis

8. Global Generic Oncology Drugs Market Analysis 2013-2022 and Forecast 2023-2033, By Molecule Type

  • 8.1. Introduction / Key Findings
  • 8.2. Historical Market Size (US$ Mn) Analysis, by Molecule Type, 2013-2022
  • 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast, by Molecule Type, 2023-2033
    • 8.3.1. Large Molecule
    • 8.3.2. Small Molecule
  • 8.4. Market Attractiveness Analysis, by Molecule Type

9. Global Generic Oncology Drugs Market Analysis 2013-2022 and Forecast 2023-2033, By Route of Administration

  • 9.1. Introduction / Key Findings
  • 9.2. Historical Market Size (US$ Mn) Analysis, By Route of Administration, 2013-2022
  • 9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast, by Route of Administration, 2023-2033
    • 9.3.1. Oral
    • 9.3.2. Parenteral
  • 9.4. Market Attractiveness Analysis, by Route of Administration

10. Global Generic Oncology Drugs Market Analysis 2013-2022 and Forecast 2023-2033, By Distribution Channel

  • 10.1. Introduction / Key Findings
  • 10.2. Historical Market Size (US$ Mn) Analysis, By Distribution Channel, 2013-2022
  • 10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast, by Distribution Channel, 2023-2033
    • 10.3.1. Hospital Pharmacy
    • 10.3.2. Retail Pharmacy
    • 10.3.3. Online Pharmacies
    • 10.3.4. Managed Care Institutions
  • 10.4. Market Attractiveness Analysis, by Distribution Channel

11. Global Generic Oncology Drugs Market Analysis 2013-2022 and Forecast 2023-2033, By Region

  • 11.1. Introduction
  • 11.2. Historical Market Size (US$ Mn) Analysis, by Region, 2013-2022
  • 11.3. Current and Future Market Value (US$ Mn) Analysis and Forecast, By Region, 2023-2033
    • 11.3.1. North America
    • 11.3.2. Latin America
    • 11.3.3. Europe
    • 11.3.4. East Asia
    • 11.3.5. South Asia
    • 11.3.6. Oceania
    • 11.3.7. Middle East and Africa (MEA)
  • 11.4. Market Attractiveness Analysis, by Region

12. North America Generic Oncology Drugs Market Analysis 2013-2022 and Forecast 2023-2033

  • 12.1. Introduction
  • 12.2. Historical Market Size (US$ Mn) Analysis, by Market Taxonomy, 2013-2022
  • 12.3. Current and Future Market Value (US$ Mn) Analysis and Forecast, by Market Taxonomy, 2023-2033
    • 12.3.1. By Country
      • 12.3.1.1. U.S.
      • 12.3.1.2. Canada
    • 12.3.2. By Molecule Type
    • 12.3.3. By Route of Administration
    • 12.3.4. By Distribution Channel
  • 12.4. Market Attractiveness Analysis
    • 12.4.1. By Country
    • 12.4.2. By Molecule Type
    • 12.4.3. By Route of Administration
    • 12.4.4. By Distribution Channel
  • 12.5. Market Trends
  • 12.6. Key Market Participants - Intensity Mapping
  • 12.7. Drivers and Restraints - Impact Analysis
  • 12.8. Country Level Analysis & Forecast
    • 12.8.1. U.S. Generic Oncology Drugs Market Analysis
      • 12.8.1.1. Introduction
      • 12.8.1.2. Market Analysis and Forecast, by Market Taxonomy
        • 12.8.1.2.1. By Molecule Type
        • 12.8.1.2.2. By Route of Administration
        • 12.8.1.2.3. By Distribution Channel
    • 12.8.2. Canada Generic Oncology Drugs Market Analysis
      • 12.8.2.1. Introduction
      • 12.8.2.2. Market Analysis and Forecast, by Market Taxonomy
        • 12.8.2.2.1. By Molecule Type
        • 12.8.2.2.2. By Route of Administration
        • 12.8.2.2.3. By Distribution Channel

13. Latin America Generic Oncology Drugs Market Analysis 2013-2022 and Forecast 2023-2033

  • 13.1. Introduction
  • 13.2. Historical Market Size (US$ Mn) Analysis, by Market Taxonomy, 2013-2022
  • 13.3. Current and Future Market Value (US$ Mn) Analysis and Forecast, by Market Taxonomy, 2023-2033
    • 13.3.1. By Country
      • 13.3.1.1. Mexico
      • 13.3.1.2. Brazil
      • 13.3.1.3. Argentina
      • 13.3.1.4. Rest of Latin America
    • 13.3.2. By Molecule Type
    • 13.3.3. By Route of Administration
    • 13.3.4. By Distribution Channel
  • 13.4. Market Attractiveness Analysis
    • 13.4.1. By Country
    • 13.4.2. By Molecule Type
    • 13.4.3. By Route of Administration
    • 13.4.4. By Distribution Channel
  • 13.5. Market Trends
  • 13.6. Key Market Participants - Intensity Mapping
  • 13.7. Drivers and Restraints - Impact Analysis
  • 13.8. Country Level Analysis & Forecast
    • 13.8.1. Mexico Generic Oncology Drugs Market Analysis
      • 13.8.1.1. Introduction
      • 13.8.1.2. Market Analysis and Forecast, by Market Taxonomy
        • 13.8.1.2.1. By Molecule Type
        • 13.8.1.2.2. By Route of Administration
        • 13.8.1.2.3. By Distribution Channel
    • 13.8.2. Brazil Generic Oncology Drugs Market Analysis
      • 13.8.2.1. Introduction
      • 13.8.2.2. Market Analysis and Forecast, by Market Taxonomy
        • 13.8.2.2.1. By Molecule Type
        • 13.8.2.2.2. By Route of Administration
        • 13.8.2.2.3. By Distribution Channel
    • 13.8.3. Argentina Generic Oncology Drugs Market Analysis
      • 13.8.3.1. Introduction
      • 13.8.3.2. Market Analysis and Forecast, by Market Taxonomy
        • 13.8.3.2.1. By Molecule Type
        • 13.8.3.2.2. By Route of Administration
        • 13.8.3.2.3. By Distribution Channel

14. Europe Generic Oncology Drugs Market Analysis 2013-2022 and Forecast 2023-2033

  • 14.1. Introduction
  • 14.2. Historical Market Size (US$ Mn) Analysis, by Market Taxonomy, 2013-2022
  • 14.3. Current and Future Market Value (US$ Mn) Analysis and Forecast, by Market Taxonomy, 2023-2033
    • 14.3.1. By Country
      • 14.3.1.1. Germany
      • 14.3.1.2. Italy
      • 14.3.1.3. France
      • 14.3.1.4. U.K.
      • 14.3.1.5. Spain
      • 14.3.1.6. BENELUX
      • 14.3.1.7. Russia
      • 14.3.1.8. Rest of Europe
    • 14.3.2. By Molecule Type
    • 14.3.3. By Route of Administration
    • 14.3.4. By Distribution Channel
  • 14.4. Market Attractiveness Analysis
    • 14.4.1. By Country
    • 14.4.2. By Molecule Type
    • 14.4.3. By Route of Administration
    • 14.4.4. By Distribution Channel
  • 14.5. Market Trends
  • 14.6. Key Market Participants - Intensity Mapping
  • 14.7. Drivers and Restraints - Impact Analysis
  • 14.8. Country Level Analysis & Forecast
    • 14.8.1. Germany Generic Oncology Drugs Market Analysis
      • 14.8.1.1. Introduction
      • 14.8.1.2. Market Analysis and Forecast, by Market Taxonomy
        • 14.8.1.2.1. By Molecule Type
        • 14.8.1.2.2. By Route of Administration
        • 14.8.1.2.3. By Distribution Channel
    • 14.8.2. Italy Generic Oncology Drugs Market Analysis
      • 14.8.2.1. Introduction
      • 14.8.2.2. Market Analysis and Forecast, by Market Taxonomy
        • 14.8.2.2.1. By Molecule Type
        • 14.8.2.2.2. By Route of Administration
        • 14.8.2.2.3. By Distribution Channel
    • 14.8.3. France Generic Oncology Drugs Market Analysis
      • 14.8.3.1. Introduction
      • 14.8.3.2. Market Analysis and Forecast, by Market Taxonomy
        • 14.8.3.2.1. By Molecule Type
        • 14.8.3.2.2. By Route of Administration
        • 14.8.3.2.3. By Distribution Channel
    • 14.8.4. U.K. Generic Oncology Drugs Market Analysis
      • 14.8.4.1. Introduction
      • 14.8.4.2. Market Analysis and Forecast, by Market Taxonomy
        • 14.8.4.2.1. By Molecule Type
        • 14.8.4.2.2. By Route of Administration
        • 14.8.4.2.3. By Distribution Channel
    • 14.8.5. Spain Generic Oncology Drugs Market Analysis
      • 14.8.5.1. Introduction
      • 14.8.5.2. Market Analysis and Forecast, by Market Taxonomy
        • 14.8.5.2.1. By Molecule Type
        • 14.8.5.2.2. By Route of Administration
        • 14.8.5.2.3. By Distribution Channel
    • 14.8.6. BENELUX Generic Oncology Drugs Market Analysis
      • 14.8.6.1. Introduction
      • 14.8.6.2. Market Analysis and Forecast, by Market Taxonomy
        • 14.8.6.2.1. By Molecule Type
        • 14.8.6.2.2. By Route of Administration
        • 14.8.6.2.3. By Distribution Channel
    • 14.8.7. Russia Generic Oncology Drugs Market Analysis
      • 14.8.7.1. Introduction
      • 14.8.7.2. Market Analysis and Forecast, by Market Taxonomy
        • 14.8.7.2.1. By Molecule Type
        • 14.8.7.2.2. By Route of Administration
        • 14.8.7.2.3. By Distribution Channel

15. East Asia Generic Oncology Drugs Market Analysis 2013-2022 and Forecast 2023-2033

  • 15.1. Introduction
  • 15.2. Historical Market Size (US$ Mn) Analysis, by Market Taxonomy, 2013-2022
  • 15.3. Current and Future Market Value (US$ Mn) Analysis and Forecast, by Market Taxonomy, 2023-2033
    • 15.3.1. By Country
      • 15.3.1.1. China
      • 15.3.1.2. Japan
      • 15.3.1.3. South Korea
    • 15.3.2. By Molecule Type
    • 15.3.3. By Route of Administration
    • 15.3.4. By Distribution Channel
  • 15.4. Market Attractiveness Analysis
    • 15.4.1. By Molecule Type
    • 15.4.2. By Route of Administration
    • 15.4.3. By Distribution Channel
  • 15.5. Market Trends
  • 15.6. Key Market Participants - Intensity Mapping
  • 15.7. Drivers and Restraints - Impact Analysis
  • 15.8. Country Level Analysis & Forecast
    • 15.8.1. China Generic Oncology Drugs Market Analysis
      • 15.8.1.1. Introduction
      • 15.8.1.2. Market Analysis and Forecast, by Market Taxonomy
        • 15.8.1.2.1. By Molecule Type
        • 15.8.1.2.2. By Route of Administration
        • 15.8.1.2.3. By Distribution Channel
    • 15.8.2. Japan Generic Oncology Drugs Market Analysis
      • 15.8.2.1. Introduction
      • 15.8.2.2. Market Analysis and Forecast, by Market Taxonomy
        • 15.8.2.2.1. By Molecule Type
        • 15.8.2.2.2. By Route of Administration
        • 15.8.2.2.3. By Distribution Channel
    • 15.8.3. South Korea Generic Oncology Drugs Market Analysis
      • 15.8.3.1. Introduction
      • 15.8.3.2. Market Analysis and Forecast, by Market Taxonomy
        • 15.8.3.2.1. By Molecule Type
        • 15.8.3.2.2. By Route of Administration
        • 15.8.3.2.3. By Distribution Channel

16. South Asia Generic Oncology Drugs Market Analysis 2013-2022 and Forecast 2023-2033

  • 16.1. Introduction
  • 16.2. Historical Market Size (US$ Mn) Analysis, by Market Taxonomy, 2013-2022
  • 16.3. Current and Future Market Value (US$ Mn) Analysis and Forecast, by Market Taxonomy, 2023-2033
    • 16.3.1. By Country
      • 16.3.1.1. India
      • 16.3.1.2. Indonesia
      • 16.3.1.3. Malaysia
      • 16.3.1.4. Thailand
      • 16.3.1.5. Rest of South Asia
    • 16.3.2. By Molecule Type
    • 16.3.3. By Route of Administration
    • 16.3.4. By Distribution Channel
  • 16.4. Market Attractiveness Analysis
    • 16.4.1. By Country
    • 16.4.2. By Molecule Type
    • 16.4.3. By Route of Administration
    • 16.4.4. By Distribution Channel
  • 16.5. Market Trends
  • 16.6. Key Market Participants - Intensity Mapping
  • 16.7. Drivers and Restraints - Impact Analysis
  • 16.8. Country Level Analysis & Forecast
    • 16.8.1. India Generic Oncology Drugs Market Analysis
      • 16.8.1.1. Introduction
      • 16.8.1.2. Market Analysis and Forecast, by Market Taxonomy
        • 16.8.1.2.1. By Molecule Type
        • 16.8.1.2.2. By Route of Administration
        • 16.8.1.2.3. By Distribution Channel
    • 16.8.2. Indonesia Generic Oncology Drugs Market Analysis
      • 16.8.2.1. Introduction
      • 16.8.2.2. Market Analysis and Forecast, by Market Taxonomy
        • 16.8.2.2.1. By Molecule Type
        • 16.8.2.2.2. By Route of Administration
        • 16.8.2.2.3. By Distribution Channel
    • 16.8.3. Malaysia Generic Oncology Drugs Market Analysis
      • 16.8.3.1. Introduction
      • 16.8.3.2. Market Analysis and Forecast, by Market Taxonomy
        • 16.8.3.2.1. By Molecule Type
        • 16.8.3.2.2. By Route of Administration
        • 16.8.3.2.3. By Distribution Channel
    • 16.8.4. Thailand Generic Oncology Drugs Market Analysis
      • 16.8.4.1. Introduction
      • 16.8.4.2. Market Analysis and Forecast, by Market Taxonomy
        • 16.8.4.2.1. By Molecule Type
        • 16.8.4.2.2. By Route of Administration
        • 16.8.4.2.3. By Distribution Channel

17. Oceania Generic Oncology Drugs Market 2013-2022 and Forecast 2023-2033

  • 17.1. Introduction
  • 17.2. Historical Market Size (US$ Mn) Analysis, by Market Taxonomy, 2013-2022
  • 17.3. Current and Future Market Value (US$ Mn) Analysis and Forecast, by Market Taxonomy, 2023-2033
    • 17.3.1. By Country
      • 17.3.1.1. Australia
      • 17.3.1.2. New Zealand
    • 17.3.2. By Molecule Type
    • 17.3.3. By Route of Administration
    • 17.3.4. By Distribution Channel
  • 17.4. Market Attractiveness Analysis
    • 17.4.1. By Country
    • 17.4.2. By Molecule Type
    • 17.4.3. By Route of Administration
    • 17.4.4. By Distribution Channel
  • 17.5. Key Market Participants - Intensity Mapping
  • 17.6. Key Market Participants - Intensity Mapping
  • 17.7. Drivers and Restraints - Impact Analysis
  • 17.8. Country Level Analysis & Forecast
    • 17.8.1. Australia Generic Oncology Drugs Market Analysis
      • 17.8.1.1. Introduction
      • 17.8.1.2. Market Analysis and Forecast, by Market Taxonomy
        • 17.8.1.2.1. By Molecule Type
        • 17.8.1.2.2. By Route of Administration
        • 17.8.1.2.3. By Distribution Channel
    • 17.8.2. New Zealand Generic Oncology Drugs Market Analysis
      • 17.8.2.1. Introduction
      • 17.8.2.2. Market Analysis and Forecast, by Market Taxonomy
        • 17.8.2.2.1. By Molecule Type
        • 17.8.2.2.2. By Route of Administration
        • 17.8.2.2.3. By Distribution Channel

18. Middle East and Africa (MEA) Generic Oncology Drugs Market Analysis 2013-2022 and Forecast 2023-2033

  • 18.1. Introduction
  • 18.2. Historical Market Size (US$ Mn) Analysis, by Market Taxonomy, 2013-2022
  • 18.3. Current and Future Market Value (US$ Mn) Analysis and Forecast, by Market Taxonomy, 2023-2033
    • 18.3.1. By Country
      • 18.3.1.1. GCC Countries
      • 18.3.1.2. Turkey
      • 18.3.1.3. South Africa
      • 18.3.1.4. North Africa
      • 18.3.1.5. Rest of Middle East and Africa
    • 18.3.2. By Molecule Type
    • 18.3.3. By Route of Administration
    • 18.3.4. By Distribution Channel
  • 18.4. Market Attractiveness Analysis
    • 18.4.1. By Country
    • 18.4.2. By Molecule Type
    • 18.4.3. By Route of Administration
    • 18.4.4. By Distribution Channel
  • 18.5. Market Trends
  • 18.6. Key Market Participants - Intensity Mapping
  • 18.7. Drivers and Restraints - Impact Analysis
  • 18.8. Country Level Analysis & Forecast
    • 18.8.1. GCC Countries Generic Oncology Drugs Market Analysis
      • 18.8.1.1. Introduction
      • 18.8.1.2. Market Analysis and Forecast, by Market Taxonomy
        • 18.8.1.2.1. By Molecule Type
        • 18.8.1.2.2. By Route of Administration
        • 18.8.1.2.3. By Distribution Channel
    • 18.8.2. Turkey Generic Oncology Drugs Market Analysis
      • 18.8.2.1. Introduction
      • 18.8.2.2. Market Analysis and Forecast, by Market Taxonomy
        • 18.8.2.2.1. By Molecule Type
        • 18.8.2.2.2. By Route of Administration
        • 18.8.2.2.3. By Distribution Channel
    • 18.8.3. South Africa Generic Oncology Drugs Market Analysis
      • 18.8.3.1. Introduction
      • 18.8.3.2. Market Analysis and Forecast, by Market Taxonomy
        • 18.8.3.2.1. By Molecule Type
        • 18.8.3.2.2. By Route of Administration
        • 18.8.3.2.3. By Distribution Channel
    • 18.8.4. North Africa Generic Oncology Drugs Market Analysis
      • 18.8.4.1. Introduction
      • 18.8.4.2. Market Analysis and Forecast, by Market Taxonomy
        • 18.8.4.2.1. By Molecule Type
        • 18.8.4.2.2. By Route of Administration
        • 18.8.4.2.3. By Distribution Channel

19. Market Structure Analysis

  • 19.1. Market Analysis, by Tier of Companies
  • 19.2. Market Share Analysis of Top Players
  • 19.3. Market Concentration
  • 19.4. Market Presence Analysis

20. Competition Analysis

  • 20.1. Competition Dashboard
  • 20.2. Competition Deep Dive
    • 20.2.1. Bausch Health Companies Inc.
      • 20.2.1.1. Overview
      • 20.2.1.2. Product Portfolio
      • 20.2.1.3. Sales Footprint
      • 20.2.1.4. Key Financials
      • 20.2.1.5. SWOT Analysis
      • 20.2.1.6. Strategy Overview
        • 20.2.1.6.1. Marketing Strategy
        • 20.2.1.6.2. Product Strategy
        • 20.2.1.6.3. Channel Strategy
    • 20.2.2. Novartis
      • 20.2.2.1. Overview
      • 20.2.2.2. Product Portfolio
      • 20.2.2.3. Sales Footprint
      • 20.2.2.4. Key Financials
      • 20.2.2.5. SWOT Analysis
      • 20.2.2.6. Strategy Overview
        • 20.2.2.6.1. Marketing Strategy
        • 20.2.2.6.2. Product Strategy
        • 20.2.2.6.3. Channel Strategy
    • 20.2.3. Pfizer
      • 20.2.3.1. Overview
      • 20.2.3.2. Product Portfolio
      • 20.2.3.3. Sales Footprint
      • 20.2.3.4. Key Financials
      • 20.2.3.5. SWOT Analysis
      • 20.2.3.6. Strategy Overview
        • 20.2.3.6.1. Marketing Strategy
        • 20.2.3.6.2. Product Strategy
        • 20.2.3.6.3. Channel Strategy
    • 20.2.4. GSK
      • 20.2.4.1. Overview
      • 20.2.4.2. Product Portfolio
      • 20.2.4.3. Sales Footprint
      • 20.2.4.4. Key Financials
      • 20.2.4.5. SWOT Analysis
      • 20.2.4.6. Strategy Overview
        • 20.2.4.6.1. Marketing Strategy
        • 20.2.4.6.2. Product Strategy
        • 20.2.4.6.3. Channel Strategy
    • 20.2.5. Celgene
      • 20.2.5.1. Overview
      • 20.2.5.2. Product Portfolio
      • 20.2.5.3. Sales Footprint
      • 20.2.5.4. Key Financials
      • 20.2.5.5. SWOT Analysis
      • 20.2.5.6. Strategy Overview
        • 20.2.5.6.1. Marketing Strategy
        • 20.2.5.6.2. Product Strategy
        • 20.2.5.6.3. Channel Strategy
    • 20.2.6. Teva Pharmaceuticals
      • 20.2.6.1. Overview
      • 20.2.6.2. Product Portfolio
      • 20.2.6.3. Sales Footprint
      • 20.2.6.4. Key Financials
      • 20.2.6.5. SWOT Analysis
      • 20.2.6.6. Strategy Overview
        • 20.2.6.6.1. Marketing Strategy
        • 20.2.6.6.2. Product Strategy
        • 20.2.6.6.3. Channel Strategy
    • 20.2.7. Merck & Company
      • 20.2.7.1. Overview
      • 20.2.7.2. Product Portfolio
      • 20.2.7.3. Sales Footprint
      • 20.2.7.4. Key Financials
      • 20.2.7.5. SWOT Analysis
      • 20.2.7.6. Strategy Overview
        • 20.2.7.6.1. Marketing Strategy
        • 20.2.7.6.2. Product Strategy
        • 20.2.7.6.3. Channel Strategy
    • 20.2.8. Aurobindo Pharma
      • 20.2.8.1. Overview
      • 20.2.8.2. Product Portfolio
      • 20.2.8.3. Sales Footprint
      • 20.2.8.4. Key Financials
      • 20.2.8.5. SWOT Analysis
      • 20.2.8.6. Strategy Overview
        • 20.2.8.6.1. Marketing Strategy
        • 20.2.8.6.2. Product Strategy
        • 20.2.8.6.3. Channel Strategy
    • 20.2.9. Hikma Pharmaceuticals
      • 20.2.9.1. Overview
      • 20.2.9.2. Product Portfolio
      • 20.2.9.3. Sales Footprint
      • 20.2.9.4. Key Financials
      • 20.2.9.5. SWOT Analysis
      • 20.2.9.6. Strategy Overview
        • 20.2.9.6.1. Marketing Strategy
        • 20.2.9.6.2. Product Strategy
        • 20.2.9.6.3. Channel Strategy
    • 20.2.10. Mylan
      • 20.2.10.1. Overview
      • 20.2.10.2. Product Portfolio
      • 20.2.10.3. Sales Footprint
      • 20.2.10.4. Key Financials
      • 20.2.10.5. SWOT Analysis
      • 20.2.10.6. Strategy Overview
        • 20.2.10.6.1. Marketing Strategy
        • 20.2.10.6.2. Product Strategy
        • 20.2.10.6.3. Channel Strategy
    • 20.2.11. NATCO Pharma
      • 20.2.11.1. Overview
      • 20.2.11.2. Product Portfolio
      • 20.2.11.3. Sales Footprint
      • 20.2.11.4. Key Financials
      • 20.2.11.5. SWOT Analysis
      • 20.2.11.6. Strategy Overview
        • 20.2.11.6.1. Marketing Strategy
        • 20.2.11.6.2. Product Strategy
        • 20.2.11.6.3. Channel Strategy

21. Assumptions and Acronyms Used

22. Research Methodology